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Abstract
Adult vertebrates have retained the ability to regenerate peripheral nerves after injury,
although regeneration is frequently incomplete, often leading to functional impairments.
Small molecule screens using whole organisms have high potential to identify biologically
relevant targets, yet currently available assays for in vivo peripheral nerve regeneration are
either very laborious and/or require complex technology. Here we take advantage of the
optical transparency of larval zebrafish to develop a simple and fast pectoral fin removal
assay that measures peripheral nerve regeneration in vivo. Twenty-four hours after fin
amputation we observe robust and stereotyped nerve regrowth at the fin base. Similar to
laser mediated nerve transection, nerve regrowth after fin amputation requires Schwann
cells and FGF signaling, confirming that the fin amputation assay identifies pathways rele-
vant for peripheral nerve regeneration. From a library of small molecules with known targets,
we identified 21 compounds that impair peripheral nerve regeneration. Several of these
compounds target known regulators of nerve regeneration, further validating the fin removal
assay. Twelve of the identified compounds affect targets not previously known to control
peripheral nerve regeneration. Using a laser-mediated nerve transection assay we tested
ten of those compounds and confirmed six of these compounds to impair peripheral nerve
regeneration: an EGFR inhibitor, a glucocorticoid, prostaglandin D2, a retinoic acid agonist,
an inhibitor of calcium channels and a topoisomerase I inhibitor. Thus, we established a
technically simple assay to rapidly identify valuable entry points into pathways critical for ver-
tebrate peripheral nerve regeneration.
Introduction
Insults such as physical trauma, chemotherapy or metabolic disorders can lead to peripheral
nerve damage [1, 2]. Given the diversity of insults, it is not surprising that peripheral nerve
damage has a high incidence rate that is even higher in the elderly population [3–5]. Unlike
the central nervous system (CNS), the peripheral nervous system has retained considerable
capacity for axonal regeneration. This is in part due to the ability of PNS neurons to mount a
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cell-intrinsic growth-promoting response and to an environment amiable to axonal regenera-
tion [6]. Yet despite their remarkable ability for regeneration, functional regeneration often
remains incomplete [1, 7]. Therefore, novel treatment strategies to enhance the robustness and
fidelity of peripheral nerve regeneration would be beneficial.
Small molecule screens in zebrafish have been highly successful to identify bioactive com-
pounds that control various biological processes including rest/wake regulation [8], cancer [9,
10], hair cell regeneration [11], metabolism [12], haematopoietic stem cell homeostasis [13],
and BMP signaling [14]. We have recently developed a laser mediated nerve transection assay
to visualize and quantify peripheral nerve regeneration in larval zebrafish [15, 16]. This assay
has yielded invaluable insights into the cellular and molecular mechanisms that promote axon
regrowth and directionality [15–18]. While powerful, this assay is limited as a screening tool
by its very low throughput. To circumvent this limitation, we developed a simple and fast
assay to monitor regeneration of peripheral nerves innervating pectoral fins. After pectoral fin
removal, we assessed axonal regrowth at the fin base. Using this high throughput in vivo assay
we screened over 340 compounds with known targets which led to the identification of several
targets previously not implicated in axonal regeneration.
Results
Pectoral fin removal induces robust nerve regeneration
In zebrafish larvae the pectoral fins are innervated by the four anterior-most segmental spinal
nerves, comprised predominantly of motor axons. The first three segmental nerves form a
plexus at the dorsal-most aspect of the fin and the fourth nerve travels along the body wall
before it enters the fin at the ventral-most aspect [19, 20]. All four nerves contribute to a ring-
like nerve network at the fin base from which several branches extend to innervate the fin mus-
culature (Fig 1A–1C) [19, 20]. Using tweezers, we severed the pectoral fin including the ring-
like nerve network at the fin base (Fig 1D). Importantly, this surgery leaves behind a proximal
nerve stump located at the dorsal plexus and the ventral-most aspect of the fin (Fig 1D). By 24
hours post fin removal, regenerating Tg(mnx1:GFP) positive axons had re-established the ring-
like nerve network at the fin base (Fig 1E). Regeneration was remarkably robust resulting in
the formation of a ring-like nerve network in 100% of pectoral fins (n = 66/66, Fig 1E). More-
over, surgery and regeneration analysis including post-injury imaging was rapid, allowing
analysis of about 160 pectoral fins within 2 days. Thus, following pectoral fin removal we
observed robust axonal regrowth in vivo.
Amputation induced nerve transection exhibits key features of vertebrate
peripheral nerve regeneration
Fin removal leaves behind an open wound and constitutes an amputation injury. This is in
contrast to nerve crush or nerve transection injuries, and therefore prompted us to determine
if and to what extent the cellular and molecular aspects of nerve regrowth after fin removal
resembles those of transection-induced nerve regeneration. We therefore tested whether
Schwann cells and FGF signaling play as important roles in peripheral nerve regeneration after
fin amputation as observed following crush injury in rodents or laser mediated nerve transec-
tion in zebrafish [16, 18, 21–25]. To quantify the extent of axon regeneration at 24 hours after
fin removal, we applied a three-category rubrics illustrated in Fig 2A–2C. We have previously
shown that genetic ablation of Schwann cells in sox10 mutants or acute ablation of Schwann
cells severely compromises spinal motor nerves following nerve transection [16]. In contrast to
wild type siblings, regenerating axons in fin amputated sox10 mutants failed to reform the
Nerve regeneration drug screen
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ring-like nerve network at the fin base in 50% of the fins examined and stalled prematurely
(Fig 2D–2F). Similar to the dependence on Schwann cells, FGF signaling has been shown to
promote peripheral nerve regeneration in rodents [21–25]. We observed significantly and
dose-dependently reduced axon regrowth at the fin base in larvae treated with the FGF inhibi-
tor SU5402 (Fig 2G–2J). Thus, axonal regeneration following fin amputation requires the pres-
ence of Schwann cell as well as FGF signaling, two hallmarks of peripheral nerve regeneration.
A small molecule screen for compounds that control amputation induced
nerve regeneration
Having established a robust and rapid assay with hallmarks of vertebrate peripheral nerve
regeneration, we next screened the ICCB Known Bioactives library (Enzo), containing 480
bioactive compounds with known biological targets to identify molecular pathways promot-
ing nerve regrowth. We first screened the library for effects on survival and excluded 134
Fig 1. Pectoral fin innervation and nerve regrowth after fin removal. (A-B) Dorsal (A) and side view (B) of
a larval zebrafish at 5 dpf showing the location of the pectoral fin (magenta dashed box). (C, C’) Pectoral fin
innervation in a Tg(mnx1:GFP) transgenic larva at 5 dpf (C) and a schematic (C’). The first segmental nerve
(orange) forms the dorsal plexus together with the joint nerves 2 and 3 (red). The fourth nerve (green) travels
along the larval body wall, before it enters the pectoral fin ventrally. These nerves contribute to the ring-like
network at the fin base (blue). (D-E) Fin region of Tg(mnx1:GFP) transgenic larvae 1 hour (D) and 24 hours
(E) after fin removal. One hour after the pectoral fin has been removed using tweezers, GFP positive axons at
the fin base are no longer detectable, leaving behind the stumps of nerve 1–3 (orange, red) at the dorsal
plexus and at the 4th nerve entry point (green, D). Twenty-four hours after fin removal, GFP positive axons at
the fin base have regrown robustly, reforming the ring-like nerve network at the fin base (blue) in 100% of the
66 control fish tested (untreated and DMSO treated, E).
https://doi.org/10.1371/journal.pone.0178854.g001
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compounds that compared to 1% DMSO exposure diminished overall health (see Material
and methods for details) over the course of 48 hours. We then combined the remaining 346
compounds into 69 distinct pools (Fig 3, S1 Table). Each of these pools was then added to a
group of four larvae immediately following fin amputation. In DMSO treated controls, regen-
erating axons re-formed a ring-like nerve network at the fin base 24 hours after fin removal
(Figs 1E and 2G). In larvae exposed to fifteen pools, regenerating axons failed to form the
characteristic ring-like network. Specifically, seven pools predominantly caused defasciculated
Fig 2. Nerve regrowth at the fin base requires sox10 and FGF. (A-C) Quantification of fin nerve regrowth in Tg(mnx1:GFP) transgenic larvae 24 hours
after fin removal; nerves show different degrees of nerve regrowth (A-C). Categories 0, 1, and 2 indicate that none (A, A’), one (B, B’), or both sides (C,C’)
of the ring-like nerve network at the fin base regrew, respectively. (A’-C’): schematic representation of these results. (D-F) Nerve regrowth at the fin base
24 hours after fin removal in a wild type sibling (D) and a sox10 mutant (E). Sox10 mutants display significantly reduced nerve regrowth compared to wild
type siblings. Graphical representation of the extent of nerve regrowth (category 0, 1, 2; F). (G-J) Nerve regrowth at the fin base at 24 hours after fin
removal in a control larva treated with DMSO (G) and larvae treated with a low (17μM, H) or a high dose (34μM, I) of the FGF inhibitor SU5402. DMSO or
SU5402 were added immediately after fin amputation. FGF inhibitor-treated larvae show significantly less nerve regrowth compared to DMSO-treated
controls. Graphical representation of the extent of nerve regrowth (category 0, 1, 2; J). All scale bars are 10 μm.
https://doi.org/10.1371/journal.pone.0178854.g002
Nerve regeneration drug screen
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Fig 3. Small molecule screen workflow. For simplicity a single 96-well plate containing active compounds is shown. First we tested the
toxicity of the individual compounds on larval zebrafish and excluded 134 toxic compounds from further analysis (black wells). We chose
to apply the compounds at a uniform dilution of 1:1,000 since this ensured a fast throughput and a relatively low percentage of toxic
compounds. Depending on the stock concentration, most compounds were tested at a final concentration of 1 μM or 5 μg/ml with some
exceptions (S1 Table). 346 remaining compounds were assigned to 69 pools. Here, examples of two pools are shown (yellow and
Nerve regeneration drug screen
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regrowth while eight pools predominantly reduced regrowth (Fig 3, S1 Table). We next tested
each of the compounds within a given pool individually. In three of the pools we failed to
identify a singly effective compound. In the remaining 12 pools we identified 1–3 compounds
per pool totaling 21 compounds which caused impaired axonal regrowth (Fig 3, Table 1, S1
Table). Seven compounds inhibited pathways such as the MAPK pathway previously shown
to promote axon regeneration in vivo, further demonstrating the validity of the fin removal
assay (Table 1, S1 Table). Of the remaining 14 compounds, four impaired regeneration while
the presumptive action of the compound had previously been reported to promote regenera-
tion. These compounds included the retinoic acid (RA) agonists AM-580 and 9-cis-retinoic
acid, the corticosteroid signaling agonist dexamethasone, and the calcium channel blocker
verapamil (Table 1). Finally, we identified ten compounds whose presumptive action was pre-
viously not known to control peripheral nerve regeneration in vivo. Two compounds (C2
dihydroceramide and tyrphostin-1) have no known targets and were not further tested. The
remaining eight compounds included the topoisomerase I inhibitor 10-Hydroxycamptothecin
(10-HCT), the fatty acid 9(S)-HpODE, the cannabinoid receptor agonist anandamide (22:4,n-
6), the cyclic nucleotide-dependent protein kinase inhibitor HA-1004, the EGFR inhibitor
lavendustin A, the SOD mimetic MnTBAP, the TRPP3 channel inhibitor phenamil, and pros-
taglandin D2 (PGD2) (Table 1).
Compound validation using a laser based nerve transection assay
We next asked whether the compounds that impaired regeneration primarily inhibited wound
healing or acted more directly on pathways that stimulate peripheral nerve regeneration. To
distinguish between these possibilities, we used a laser to directly transect peripheral nerves,
thereby minimizing collateral damage to other tissues [17, 39]. In brief, this well-established
assay utilizes a dye laser (MicroPoint, Andor Technology) to transect the ventral or the dorsal
nerve branch of individual, GFP positive motor nerves within the first ~20 μm of their periph-
eral trajectory [15–17]. We have previously shown that within 48 hours post transection
injured motor axons exhibit robust regrowth towards their original targets resulting in func-
tional regeneration [15–17]. Importantly, larvae were exposed to the compounds from 4 hours
before transection until 48 hours post nerve transection, when axonal regeneration was scored
(Fig 3). We tested 7 of the 8 compounds that affect known targets and whose presumptive
actions were previously not known to affect peripheral nerve regeneration, as well as 3 of the 4
compounds that impaired regeneration but the presumptive action of the compound had pre-
viously been reported to promote regeneration. As a positive control, we tested the FGF inhibi-
tor SU5402 and found that similar to impairing nerve regrowth following pectoral fin removal
(Fig 2G–2J), SU5402 dose-dependently inhibited nerve regeneration following laser nerve
transection (Fig 4A).
Using this assay, four of the ten tested compounds, the cannabinoid agonist anandamide,
the inhibitor of cyclic nucleotide-dependent protein kinases HA-1004, the TRPP3 channel
inhibitor phenamil, and the SOD mimetic MnTBAP failed to exhibit any effects on nerve
regeneration (Fig 4B), suggesting that instead of targeting nerve specific regeneration path-
ways, they primarily affected tissue regeneration. In contrast, six of the ten compounds
appeared to selectively target nerve regeneration, including the EGFR inhibitor lavendustin,
orange). In a first pass, we tested the 69 compound pools for their effect on nerve regrowth in the fin removal assay and found 15 pools
that affected nerve regrowth (differently colored pools). Then we tested the individual compounds from these 15 pools in a second pass
and identified 21 individual compounds that affected nerve regrowth in the fin removal assay. Ten of these compounds were further tested
using laser nerve transection. Timeline diagrams of treatment after fin removal and laser nerve transection are shown on the right side.
https://doi.org/10.1371/journal.pone.0178854.g003
Nerve regeneration drug screen
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the glucocorticoid receptor agonist dexamethasone, the RA receptor agonist AM580, prosta-
glandin D2 (PGD2), the calcium channel blocker verapamil, and the topoisomerase I inhibitor
10-HCT (Fig 4B–4I). Thus, pre-screening a small compound library using the fin removal
assay identified six compounds whose presumptive action was previously not known to inhibit
peripheral nerve regeneration in vivo.
Table 1. Compounds affecting nerve regrowth in the fin removal assay. Compound name, presumptive action and previous studies about the role of the
compound target in axonal/ nerve regeneration including references. Compounds tested by laser nerve transection are marked in the last column. Blue color
highlights compounds whose presumptive action was expected to impair nerve regeneration based on previous reports. Red color highlights compounds
whose presumptive action had been shown to have opposite effects on nerve regeneration. Compounds whose presumptive action has not been shown to
control nerve regeneration are marked in white (compounds with no known targets) and yellow (with known targets).
Compound name Presumptive action Role of the compound target in axonal/ nerve
regeneration
Reference Tested by laser
nerve transection
SB 202190 p38 MAPK inhibitor Impaired regeneration in p38 knockout mice after crush
injury.
[26]
SB 203580 p38 MAPK inhibitor
SP-600125 JNK inhibitor JNK inhibitors delayed functional recovery/ delayed
sensory nerve innervation to the skin after sciatic nerve
transection in mice.
[27]
U-0126 MEK1/2 inhibitor Erk1/2 activation promoted robust retinal ganglion cells
neuroprotection after optic nerve injury.
[28]
Go6976 inhibitor of PKC, TrkA/B, TrkB,
JAK2/3
NGF enhanced axonal regeneration in vitro and in vivo. [29]
pifithrin p53 inhibitor 1. Pharmacological enhancement of the MDM2/p53-IGF1R
axis enhanced axonal sprouting as well as functional
recovery after spinal cord injury.
2. Significant impairment in locomotor recovery in p53 KO
versus WT mice spinal cord dorsal hemisection injury
model.
1.[30]
2.[31]
roscovitine CDK 2, 5, 7, 9 inhibitor 1. Roscovitine inhibited regeneration of facial nerve axons
after crush injury in rats.
2. Schwann cells migrated less after roscovitine treatment
in vitro and DRG neurites grow less in co-culture with
Schwann cells.
1.[32]
2.[33]
9-cis retinoic acid retinoid X receptor agonist Retinoic acid improved regeneration after nerve
transection in rats.
[34] AM580 was tested
AM-580 retinoic acid receptor agonist x
dexamethasone corticosteroid Dexamethasone enhanced functional recovery after nerve
crush injury in rats.
[35] x
verapamil L-type calcium channel inhibitor 1. Calcium channel inhibitor Nimodipin improved
regeneration after nerve crush injury.
2. Calcium channel inhibitor Nifedipin improved
regeneration after nerve crush injury.
1.[36]
2.[37]
x
C2 dihydroceramide inactive
tyrphostin 1 inactive
10-hydroxycampto-
thecin (10-HCT)
topoisomerase I inhibitor not known x
9(S)-HpODE fatty acid not known
anandamide (22:4,n-6) cannabinoid ligand not known x
HA-1004 inhibitor of cyclic nucleotide-
dependent protein kinases, e.g.
PKC
in vivo effects not known (no effect of HA-1004 in vitro on
PNS regeneration)
[38] x
lavendustin A EGFR inhibitor not known x
MnTBAP SOD mimetic not known x
phenamil TRPP3 channel inhibitor not known x
prostaglandin D2 prostaglandin not known x
https://doi.org/10.1371/journal.pone.0178854.t001
Nerve regeneration drug screen
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Topoisomerase I inhibitor selectively causes death of denervated
Schwann cells
Of the six compounds whose presumptive action was previously not known to impair periph-
eral nerve regeneration, we decided to focus on the topoisomerase I inhibitor 10-HCT. Besides
Fig 4. FGF inhibitor and six additional compounds that impair nerve regeneration after fin removal also impair regeneration after laser nerve
transection. (A) Ventral nerves of Tg(mnx1:GFP) transgenic larvae were laser transected and treated with DMSO for control, or treated with a low (17μM)
or high (34μM) dose of the FGF inhibitor SU5402. Regeneration was scored 48 hours later and the graphical representation of the extent of nerve
regeneration (no/ weak, moderate, strong regeneration) is shown, demonstrating that the FGF inhibitor SU5402 significantly and dose-dependently
impairs nerve regeneration. (B) Quantification of dorsal nerve regeneration in Tg(isl1:GFP) transgenic larvae measuring the extent of dorsal nerve
regeneration (no/ weak, moderate, strong regeneration) for controls (0.5% DMSO) and all tested compounds. Post nerve transection exposure to 100μM
anandamide (cannabinoid agonist), 25μg/ml HA-1004 (PKC inhibitor), 10μg/ml phenamil (TRPP3 channel blocker), and 25μg/ml MnTBAP (SOD mimetic)
did not significantly impair nerve regeneration. However, 25μg/ml lavendustin (EGFR inhibitor), 4μM AM-580 (RA receptor agonist), 10μg/ml verapamil
(calcium channel blocker), 5μM PGD2, 25μg/ml dexamethasone (corticosteroid), and 250μM 10-HCT significantly impaired nerve regeneration. (C-I)
Ventral nerves of Tg(mnx1:GFP) transgenic larvae treated with DMSO for control (C, D), or with 125μM of the topoisomerase I inhibitor 10-HCT (E-H)
before laser nerve transection (C, E, G) and 48 hours later (D, F, H). Control DMSO-treated larva showing normal morphology of the ventral nerve before
transection (C), and robust nerve regeneration after 48 hours (D). Transected nerves treated with 10-HCT showed normal morphology before transection
(E), but failed to regenerate after injury (F). In contrast, an untransected ventral nerve treated with 10-HCT showed normal morphology at all times (G,H).
Graphical representation of the results, showing that 10-HCT significantly impaired nerve regeneration (I). (J) Change in the number of GFP-labeled
neuronal cell bodies in Tg(isl1:GFP) transgenic larvae between day 5 and day 7, treated with DMSO for control or with 125μM 10-HCT. Dorsal nerves
were either left untransected or laser transected at day 5. On average, 26 neurons were labeled per segment. There was no difference in the change of the
neuronal cell body number between DMSO and 10-HCT treated larvae when left untransected or after nerve transection, suggesting that 10-HCT did not
reduce neuronal survival. However, following laser nerve transection in both DMSO and 10-HCT treated larvae, the number of neurons decreased on
average by 3 neurons, suggesting that a subset of neurons with transected axons died.
https://doi.org/10.1371/journal.pone.0178854.g004
Nerve regeneration drug screen
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its canonical role in DNA replication [40], Topoisomerase I also promotes transcription [41],
including transcription of long genes in neurons [42]. Both proliferation of glia cells as well as
enhanced transcriptional activity in injured neurons and glia cells occur during regeneration
[43–45], yet potential roles for topoisomerase I or its inhibitor 10-HCT in this process have
not been reported. We first tested whether 10-HCT caused neuronal cell death thereby impair-
ing axonal regeneration. Analysis of both uninjured and regenerating motor neurons did
not reveal an overt loss of GFP positive motor neurons (Fig 4J). Genetic or acute ablation of
Schwann cells in zebrafish severely impairs axonal regeneration [16, 18], and we therefore
asked whether 10-HCT treatment affects the morphology or survival of Schwann cells critical
for nerve regeneration [46]. We found that in untransected nerves, 10-HCT treatment did not
affect the number of Schwann cells (Fig 5E, 5F and 5I). In contrast, 10-HCT treatment follow-
ing laser nerve transected reduced the number of Schwann cells by ~50% (Fig 5G–5I). Thus,
denervated Schwann cells are susceptible to 10-HCT treatment, consistent with the idea that
topoisomerase I promotes Schwann cell survival after injury.
Discussion
Fin removal assay as a rapid and robust screening assay for nerve
regeneration
Zebrafish adult and larvae have been used extensively to study fin regeneration, and in some
instances regeneration of individual, unmyelinated sensory axons [47, 48]. In contrast to sever-
ing the tail fin, our assay using larval zebrafish focuses on the paired pectoral fins. In general,
each spinal nerve of the zebrafish larva consists of ~60 axons and is associated with myelinat-
ing Schwann cells [16]. The pectoral fins are innervated by the anterior-most spinal nerves
which show defined innervation patterns and consist of at least 30 axons [19, 20, 49]. We
developed a simple yet robust fin removal assay that enabled us to perform the first whole
organism small molecule screen to identify pathways that promote vertebrate nerve regenera-
tion. Several lines of evidence support the validity of the fin removal assay. First, we show that
nerve regrowth following an amputation-induced nerve transection exhibits key features of
vertebrate peripheral nerve regeneration as both require Schwann cells and FGF signaling
(Figs 2 and 4) [16, 18]. Second, 7 of the 21 (33%) compounds identified in the fin removal
assay inhibit targets previously shown to promote nerve regeneration in vivo (Table 1). For
example, the fin removal assay identified four inhibitors of MAPK signaling, including a JNK
inhibitor, a MEK inhibitor, and two p38 inhibitors (Table 1). Previous studies have shown that
MAPK signaling pathways are conserved and crucial regulators of peripheral nerve regenera-
tion [26, 27, 50–53]. Third, we confirmed that the majority (6 of 10, 60%) of the compounds
that inhibited axon regeneration in the fin removal assay also impaired peripheral nerve regen-
eration in the lower-throughput but better-established laser nerve transection assay (Fig 4).
However, during the second pass of the screen, we failed to identify a singly effective com-
pound in three out of 15 compound pools (20%), which reduced nerve regrowth in the first
pass of the screen. This reflects either false positive results or an effect of two or more com-
pounds acting together to impair regeneration. Using laser nerve transections as the gold stan-
dard to test peripheral nerve regeneration, the rate of false positive results during the second
pass of the fin removal assay was also relatively high (4 of 10, 40%). Thus, the fin removal assay
is a powerful and robust screening method for identifying targets required for peripheral nerve
regeneration. Given the high false positive rate, the fin removal assay should always be com-
bined with a second independent method to study nerve regeneration. The assay can easily be
modified, for example by looking at an earlier time point, when controls have not reformed
the ring-like network at the fin base, we would be able to identify compounds which speed up
Nerve regeneration drug screen
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Fig 5. Topoisomerase I is required for survival of denervated Schwann cells following laser nerve transection. Ventral nerves of Tg(Xla.Tubb:
DsRed), Tg(sox10:NLS-Eos) double transgenic larvae treated with DMSO for control (A-D), or with the topoisomerase inhibitor 10-HCT (E-H);
untransected controls (A,B,E,F) or laser nerve transected (C,D,G,H) at different time points: before transection (A,C,E,G) or 48 hours post transection (B,
D,F,H). Graphical representation of the number of Schwann cells for the different conditions and time points (I). In DMSO controls, the number of Schwann
cells was only non-significantly marginally reduced after laser nerve transection (C,D). Similarly, in untransected control nerves, 10-HCT did not reduce
the number of Schwann cells, excluding the possibility that 10-HCT is simply toxic to Schwann cells. However, after laser nerve transection, the number of
Schwann cells was significantly reduced, suggesting that 10-HCT specifically ablated denervated Schwann cells.
https://doi.org/10.1371/journal.pone.0178854.g005
Nerve regeneration drug screen
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regeneration. Combined with targeted genome editing to generate genetic mutants, it presents
a powerful platform to identify genes that promote peripheral nerve regeneration.
Topoisomerase I inhibition selectively reduces integrity of denervated
Schwann cell
We identified six compounds that impair peripheral nerve regeneration in both the fin ampu-
tation and laser axotomy assay. The glucocorticoid dexamethasone, as well as calcium channel
inhibition and retinoid acid agonism have previously been reported to promote rather than to
inhibit axonal regeneration [34–37]. In contrast, we find that the three compounds, dexameth-
asone as well as the calcium channel inhibitor verapamil and the retinoic acid agonist AM-580
inhibit rather than promote nerve regeneration. These discrepancies might be due to differ-
ences in compound dosage, specific compound used to target a pathway, and different treat-
ment times and periods. For the remaining three compounds/targets lavendustin/EGFR,
10-HCT/topoisomerase I and PGD2 we provide the first evidence for effects on peripheral
nerve regeneration in vivo. While these compounds might directly affect axonal outgrowth, it
is also possible that these compounds primarily act on Schwann cells. For example, EGFR
signaling has been shown to promote Schwann cell migration and proliferation [54]. Similarly,
the prostanoid PGD2 has been shown activate the G-protein-coupled receptor Gpr44
expressed on Schwann cells [55].
Finally, our data reveal that the topoisomerase I inhibitor 10-HCT decreases survival of
Schwann cells associated with injured but not intact peripheral nerves (Fig 5). Topoisomerase
I inhibitors including 10-HCT are clinically used as chemotherapeutic agents in cancer therapy
by inducing DNA damage and apoptosis of proliferating cells [56, 57]. Thus, 10-HCT might
simply cause apoptosis of proliferating Schwann cells. However, in control treated animals we
did not observe an increase in Schwann cell number following laser nerve transection (Fig 5),
in line with previous findings that the early stages of peripheral nerve regeneration in zebrafish
occur independently of Schwann cells proliferation [16]. In addition to its canonical role in
DNA replication, topoisomerase I is also required for gene expression [58], and was found
more recently to control transcription of long genes [42]. Importantly, following nerve injury,
Schwann cells shed their myelin and de-differentiate to a more neural crest-/ stem cell-like
state that allows them proliferate and migrate [59]. Although we cannot exclude that 10-HCT
has a topoisomerase I-independent effect on regeneration, one attractive hypothesis is that
topoisomerase I promotes peripheral nerve regeneration by regulating gene transcription spe-
cifically in de-differentiated Schwann cells (Fig 5). Independent of its effects on Schwann cells,
topoisomerase I inhibition might also affect axonal regrowth directly. Future studies are
required to determine the precise mechanism by which 10-HCT/ topoisomerase I inhibition
affects peripheral nerve regeneration. Independent of the precise underlying mechanism, we
developed a rapid assay that combined with a whole organism small molecule screen identified
several compounds previously not known to affect peripheral nerve regeneration in vivo.
Materials and methods
Zebrafish care and strains
Protocols and procedures involving zebrafish are in compliance with the University of Penn-
sylvania Institutional Animal Care and Use Committee (IACUC) regulations, and IACUC spe-
cifically approved this study. Adult zebrafish were kept in tanks in groups of 20 to 60 fish and
fed with paramecia or dry flake food. They were exposed to a regular light-dark cycle. Water
was changed daily and water quality was tested daily. Embryos were generated by natural
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mating as described [60]. All embryos were raised at 28˚C. The Tg(mnx1:GFP)ml2 (Flanagan
[61], Tg(isl1:GFP), [62], and Tg(Xla.Tubb:DsRed)zf148 [63] transgenic lines were used to label
spinal motor nerves. The Tg(sox10:NLS-Eos)w18 [64] transgenic line was used to label Schwann
cell nuclei. All experimental and control animals were randomly distributed into control and
experimental group.
Immunohistochemistry
Embryos were fixed in 4% paraformaldehyde with 1% DMSO in 0.1 M phosphate buffer, pH
7.4, then dehydrated in methanol and permeabilized for 30 min. in acetone at -20˚C, and rehy-
drated with incubation buffer (0.2% BSA, 0.5% Triton X 100 in 0.1 M phosphate buffer, pH
7.4). The primary antibody anti-SV2 was used at 1:50 (Developmental Studies Hybridoma
Bank [DSHB]). Embryos were washed at least three times in incubation buffer before adding
the secondary antibody conjugated with Alexa Fluor 488 (1:400, Life Technologies). Antibody
incubations were performed for 4 hours at room temperature or overnight at 4˚C. Embryos
were mounted in Vectashield mounting medium (Vector laboratories), and samples were
viewed and documented as described below.
Fin removal assay
5-day-old Tg(mnx1:GFP) transgenic larval zebrafish were anesthetized using tricaine, and lar-
vae were mounted on 1.5% agarose plates molded with individual wells for each larva. Larvae
were laid on their sides and covered by 0.7% low-melt agarose containing 0.01% tricaine.
Mounted larvae were then covered by E3 medium containing tricaine. We used a stereo
microscope to view the procedure, and tweezers #5 (World Precision Instruments) to handle
the pectoral fins. For each fin amputation, the fin was lifted away from the larval body and
grasped at its base. Then we pulled the fin out and visually confirmed that the entire fin includ-
ing the base was removed. Four fish per condition were placed in a 48-well plate containing
500 μl E3 and treated with 0.5% DMSO, compound pools (each compound diluted 1:1,000) in
0.5% DMSO, or individual compounds in 0.5% DMSO. 24 hours after fin removal, larvae were
mounted in 1.2% agarose, and regrown fin nerves were imaged on a spinning disc confocal
microscope (Olympus; see below).
Small molecule screen
We used the ICCB Known Bioactives library (Enzo). Compounds were added to E3 medium
in which larval zebrafish were kept and placed in a 28˚C incubator. All larvae tested were drug
naive. To determine toxicity of compounds, we tested all compounds individually on at least
three 5-day-old larval zebrafish for 48 hours at a 1:1,000 dilution (for stock concentrations see
S1 Table). Those compounds inducing tissue necrosis, cardiac arrest, alteration of body mor-
phology, or strongly reduced responsiveness to touch after 12, 24 or 48 hours were called toxic
and excluded from further testing. Non-toxic compounds were assigned to 69 distinct pools
and tested for their effects on nerve regrowth using the fin removal assay (first-pass). Usually,
each pool was tested on four larvae, if the result was not clear (regeneration categories could
not easily be determined), the test was repeated. Pools which caused impaired regeneration in
at least half of the tested larvae (usually 2 out of 4) were called "hits". If only three larvae sur-
vived the treatment but showed normal regeneration, the pool was defined as not being a "hit".
We called regeneration abnormal if it was either category 0 or 1 regeneration or if regrowth of
the ring-like nerve network at the fin base was severely disorganized. All the individual com-
pounds in the 15 "hit" pools were tested individually in the second-pass using the fin removal
assay. Before testing the individual compounds, the highest tolerated concentration was
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determined. For this, dilutions of 1:100 to 1:1,000 were tested on 5-day-old larvae. 21 com-
pounds caused abnormal nerve regrowth at the fin base. Each compound pool had a number
code and each compound in the pool a letter code. Identity of pools and compounds was only
revealed after scoring regeneration, reducing subjective bias when scoring regeneration. The
highest tolerated dose of 10 of those compounds was tested using laser nerve transection (see
below). Control and experimental groups were treated in the same order as regeneration was
assessed to ensure approximately equal treatment duration. Treatment and assessment were
done for one group after the other.
Nerve transection by laser nerve transection
Transection of dorsal peripheral nerves was performed as previously described [15, 17]. For
scoring of dorsal and ventral nerve regrowth following laser nerve transection, we used three
categories (no/weak, moderate, strong) as introduced in [15] and adapted this scoring system
to dorsal nerves. Larvae were exposed to the compounds for at least 4 hours before and then
for 48 hours after nerve transection when regeneration was assessed.
Imaging, image processing and data analysis
Live larvae or fixed and stained embryos mounted in Vectashield (Vector laboratories) were
imaged using a spinning disk confocal microscope (Olympus). Maximum intensity projection
images of z-stacks were created using Slidebook (3i) software. Live embryos were mounted in
1.2% agarose in E3 and anesthetized in 0.022% tricaine. Confocal images were further pro-
cessed using the Image J software package (NIH). Image manipulations included adjustment
of brightness, contrast, gamma-value, and background subtraction. Manipulations were always
applied to the entire image and to all images in one experiment, ensuring that the content of
the image wasn’t altered. Images were exported and further processed in Photoshop CS4 and
final versions of the figures for the manuscript were prepared using Illustrator CS4 and Photo-
shop CS4 (Adobe). P-values were calculated using the Fisher exact test for categorical out-
comes using a Graph Pad web tool (GraphPad). Graphs were generated using Prism 5
(GraphPad).
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